PE-22-28

What it is

PE-22-28 is a synthetic peptide derived from spadin, a natural peptide the body produces when it processes a protein called sortilin. Spadin blocks a potassium channel in the brain called TREK-1, and blocking TREK-1 produces antidepressant-like effects in animals. PE-22-28 is a shortened, stabilized version designed to do the same thing with better drug-like properties.

It is an experimental research compound. It has never been tested in humans, is not FDA-approved, and is not an approved medicine anywhere. It reaches people only through research-chemical channels; any clinical use would be as an unproven compounded preparation.

All of the interest in it comes from preclinical research — animal and laboratory work, primarily from French academic groups studying TREK-1 as a target for faster-acting antidepressants.

What people use it for

How it works

PE-22-28 blocks the TREK-1 potassium channel. TREK-1 sits in brain regions involved in mood, and in animals, blocking it produces behavior that looks like a strong, fast antidepressant response — within days rather than the weeks typical of SSRIs — along with reported increases in new neuron growth and synapse formation in the hippocampus. PE-22-28 was engineered from spadin to hit this target while lasting longer in the body.

How established is this in people? It is not. The entire mechanistic story comes from animal and cell research. There is no human receptor, imaging, or clinical work confirming that blocking TREK-1 with this peptide is safe or effective in people. It is a well-defined target with an encouraging animal signal — which is exactly where many drugs look their best, right before human testing narrows or ends that promise.

What the research actually looked at

The research is preclinical. Published work examines spadin and PE-22-28 in rodent models — behavioral tests of depression, measures of hippocampal neurogenesis, and the speed of onset compared with conventional antidepressants — mostly from the French laboratories that identified spadin and the TREK-1 pathway.

There are no human trials of PE-22-28. No regulator has reviewed it, no safety database exists in people, and the doses, duration, and risks in humans are simply unknown.

Common misunderstandings

• 'It's a fast-acting antidepressant.' That describes rodents, not people. The fast onset is an animal finding; it has never been shown in a human being.
• 'It's basically a cleaner SSRI.' It works on a completely different target (a potassium channel, not serotonin reuptake), and unlike SSRIs it has no human safety or efficacy record at all.
• 'Promising research means it's close to proven.' Most compounds that look promising in animal models do not survive human testing. 'Studied in mice' is the beginning of the process, not the end.

Who it is not for

• Anyone seeking treatment for depression, anxiety, or any mental-health condition — this is not a substitute for evaluated, human-tested care.
• Anyone currently on antidepressants or other psychiatric medication, given the complete absence of human interaction or safety data.
• Pregnancy or breastfeeding, or anyone trying to conceive.
• Children and adolescents.
• Honestly, anyone who is not comfortable using a compound that has never been tested in a human being.
• Competitive athletes subject to WADA or USADA testing, who should treat any non-approved substance as prohibited by default.

If you are struggling with depression or another mood condition, the right step is an evaluation with a licensed clinician and treatments that have real human evidence behind them, not an experimental peptide. If you are in crisis, in the US you can call or text 988, the Suicide and Crisis Lifeline.

Who makes this, and under what rules

Everything dispensed here is prepared by a licensed 503A compounding pharmacy — not bought from a supplier and repackaged, and not sourced from an online seller. That designation carries specific, enforceable obligations:

• A prescription in your name. Compounded from a prescription for one identified patient, after an evaluation.
• Licensed and inspected. A state license, subject to inspection by the state board of pharmacy.
• Sterile preparation to a published standard. USP standards.
• A paper trail. A lot number and beyond-use date on every preparation.

A compounded preparation is not an FDA-approved medicine. Because PE-22-28 has never been tested in humans, a licensed provider may well decline to prescribe it — and for a condition as serious as depression, human-tested options should come first.

Where this stands

Experimental, animal-only. PE-22-28 is one of the least-tested compounds you will find discussed anywhere: a well-reasoned drug target with a genuine rodent signal and zero human data. It is included here only for honest education. It is not a proven therapy, it is not approved, and for a condition as serious as depression there are human-tested options that should come first.

Clinical detail

PE-22-28 is a synthetic analogue of spadin, a peptide derived from the sortilin propeptide (neurotensin receptor 3 / NTSR3) that antagonizes the TREK-1 (KCNK2) two-pore potassium channel. TREK-1 blockade produces antidepressant-like effects with rapid onset and increased hippocampal neurogenesis in rodent models. All supporting data is preclinical; there are no human pharmacokinetic, safety, or efficacy studies. It is not FDA-approved and has no recognized human indication.

The information on this page is general education. It is not medical advice and it is not a recommendation for any treatment. PE-22-28 has not been tested in people; its safety and effects in humans are unknown. It is not an FDA-approved medicine. A compounded preparation is not an FDA-approved product and has not been reviewed by the FDA for safety, effectiveness or quality. Descriptions of what it is used for reflect how it is discussed in research and the peptide community, not claims that it is effective or safe for any purpose. Any prescription follows an individual evaluation by a licensed provider and is issued only where that provider judges it clinically appropriate. A prescription is never guaranteed.